S. B. Kim

1987–2025 年に発表

別表記
S.B. Kim · S.-B. Kim · S-B. Kim · S B Kim · S.B Kim · S -B Kim
92
論文数
31,224
被引用数
65
h 指数
90
i10 指数

被引用数

S. B. Kim の年別被引用数1929 年: 被引用 1 件1986 年: 被引用 2 件1987 年: 被引用 2 件1988 年: 被引用 8 件1989 年: 被引用 6 件1990 年: 被引用 9 件1991 年: 被引用 2 件1992 年: 被引用 7 件1993 年: 被引用 8 件1994 年: 被引用 8 件1995 年: 被引用 15 件1996 年: 被引用 12 件1997 年: 被引用 13 件1998 年: 被引用 32 件1999 年: 被引用 66 件2000 年: 被引用 63 件2001 年: 被引用 56 件2002 年: 被引用 92 件2003 年: 被引用 82 件2004 年: 被引用 84 件2005 年: 被引用 50 件2006 年: 被引用 57 件2007 年: 被引用 55 件2008 年: 被引用 51 件2009 年: 被引用 53 件2010 年: 被引用 57 件2011 年: 被引用 55 件2012 年: 被引用 79 件2013 年: 被引用 56 件2014 年: 被引用 40 件2015 年: 被引用 54 件2016 年: 被引用 66 件2017 年: 被引用 88 件2018 年: 被引用 95 件2019 年: 被引用 155 件2020 年: 被引用 263 件2021 年: 被引用 433 件2022 年: 被引用 415 件2023 年: 被引用 323 件2024 年: 被引用 450 件2025 年: 被引用 234 件2026 年: 被引用 8 件1930〜1985 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,172 件、この内訳の 17.2%中国: 引用元論文 608 件、この内訳の 8.9%イタリア: 引用元論文 439 件、この内訳の 6.4%ドイツ: 引用元論文 384 件、この内訳の 5.6%スペイン: 引用元論文 340 件、この内訳の 5%フランス: 引用元論文 310 件、この内訳の 4.6%イギリス: 引用元論文 304 件、この内訳の 4.5%日本: 引用元論文 290 件、この内訳の 4.3%カナダ: 引用元論文 233 件、この内訳の 3.4%スイス: 引用元論文 222 件、この内訳の 3.3%韓国: 引用元論文 211 件、この内訳の 3.1%ベルギー: 引用元論文 172 件、この内訳の 2.5%
0%17.2%その他 31.2%

分野

  • Medicine44.3%
  • Physics and Astronomy20.4%
  • Biochemistry, Genetics and Molecular Biology13%
  • Environmental Science9.7%
  • Materials Science3.5%
  • Agricultural and Biological Sciences2.5%
  • その他6.6%

トピック

  • Advanced Breast Cancer Therapies5.4%
  • Neutrino Physics Research5%
  • HER2/EGFR in Cancer Research4.8%
  • Breast Cancer Treatment Studies4.7%
  • Particle physics theoretical and experimental studies4.6%
  • Cancer Immunotherapy and Biomarkers4.2%
  • その他71.3%

共著者

全論文

検索で開く
  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Silvia P. Neciosup, B.V. Offersen, Shinji Ohno, Olivia Pagani, A. Prat, Frédérique Penault‐Llorca, Hope S. Rugo, G. W. Sledge, Christoph Thomssen, D.A. Vorobiof, Theresa Wiseman, Binghe Xu, Larry Norton, A. Costa, Eric P. Winer - Annals of Oncology 2020 被引用: 1,356

  2. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

    著者: , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 435

  3. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 被引用: 378

  4. Validation of SMAP surface soil moisture products with core validation sites

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John H. Prueger, Jouni Pulliainen, Kimmo Rautiainen, Judith Ramos, M. S. Seyfried, Patrick J. Starks, Zhongbo Su, Yijian Zeng, R. van der Velde, M. Thibeault, Wouter Dorigo, Mariëtte Vreugdenhil, Jeffrey P. Walker, Xiaoling Wu, A. Monerris, Peggy O’Neill, Dara Entekhabi, E. G. Njoku, Simon Yueh - Remote Sensing of Environment 2017 被引用: 739

  5. ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

    著者: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 218

  6. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

    著者: , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 108

  7. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

    著者: , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 266

  8. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 107

  9. Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Catherine Oakman, Felipe Melo Cruz, Fábio Franke, André Mattar, E.H. Silva, Katsuki Arima Tiscoski, Wei Chen, Wěi Li, Zhongsheng Tong, Jing Wang, Shaomeng Wang, X. Wang, Jiong Wu, Xiao‐Yuan Wu, Ju Yang, Q. Zhang, Till‐Oliver Emde, G. Gaffunder, Carsten Hielscher, Michael P. Lux, Christian Schem, Manfred Welslau, Claudia Schumacher, I. Kuchuk, T Peretz, Larisa Ryvo, R. Yerushalmi, Hee Dong Chae, Y.S. Chae, Seock‐Ah Im, Hwa Jung Kim, Jie‐Hyun Kim, S.-B. Kim, Jung Eun Lee, Y. H. Park, Joohyuk Sohn, Michał Jarząb, Monika Nowaczyk, Zbigniew Nowecki, Tadeusz Pieńkowski, Marek Z. Wojtukiewicz, Piotr J. Wysocki, E. Fomin, I. P. Ganshina, Nikolay Kislov, М. В. Копп, Н. В. Коваленко, Y. Makarova, Marina Matrosova, Р. В. Орлова, Artem Poltoratsky, Р. Р. Сафин, Р. А. Зуков, A. Wong, Yoon Sim Yap, M.A. Coccia-Portugal, Nicolaas H. Fourie, R. Khanyile, L. Schoeman, Ta‐Chung Chao, S.-T. Chen, Wei‐Pang Chung, Yin‐Hsun Feng, Yung‐Chang Lin, Thitiya Dejthevaporn, Napa Parinyanitikul, Chirawadee Sathitruangsak, Areewan Somwangprasert, Piyawan Tienchaianada, Ahmet Alacacıoğlu ほか 31 名 - Journal of Clinical Oncology 2024 被引用: 63

  10. 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 58

  11. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

    著者: , , , , , , , , , , , , , , , , , , , , - ESMO Open 2024 被引用: 67

  12. 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 58

  13. Evidence for Oscillation of Atmospheric Neutrinos

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , L. Sulak, C. W. Walter, M. Goldhaber, T. Barszczxak, D. Casper, W. Gajewski, P. G. Halverson, Jonathan Y. Hsu, W. R. Kropp, L. R. Price, F. Reines, M. Smy, H. W. Sobel, M. R. Vagins, K. S. Ganezer, W. E. Keig, R. W. Ellsworth, S. Tasaka, J. Flanagan, A. Kibayashi, J. G. Learned, S. Matsuno, V. J. Stenger, D. Takemori, T. Ishii, J. Kanzaki, T. Kobayashi, S. Mine, K. Nakamura, K. Nishikawa, Y. Oyama, Akito Sakai, M. Sakuda, O. Sasaki, S. Echigo, M. Kohama, Y. Suzuki, T. J. Haines, E. Blaufuss, B. K. Kim, R. Sanford, R. Svoboda, M. L. Chen, Z. Conner, J. A. Goodman, G. W. Sullivan, J. Hill, C. K. Jung, K. Martens, C. Mauger, C. McGrew, E. Sharkey, B. Viren, C. Yanagisawa, W. Doki, K. Miyano, H. Okazawa, C. Saji, M. Takahata, Y. Nagashima, M. Takita, Tomohiro Yamaguchi, M. Yoshida, S. B. Kim, Masato Eto, K. Fujita, T. Hasegawa, T. Hasegawa, S. Hatakeyama, T. Iwamoto ほか 21 名 - Physical Review Letters 1998 被引用: 5,093

  14. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

    著者: , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 88

  15. 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)

    著者: , , , , , , , , , , , , , , - ESMO Open 2024 被引用: 20

  16. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dirk De Ruysscher, Elisabeth G.E. de Vries, Rebecca Dent, Jean-Yves Douillard, Domenico D’Ugo, Rafał Dziadziuszko, Corinne Faivre‐Finn, Eudald Felip, M.C. Garassino, Pilar Garrido, Nicolas Girard, Rob Glynne‐Jones, V. Golfinopoulos, John B.A.G. Haanen, E. Hamilton, Pasi A. Jänne, Karin Jordan, Ravindran Kanesvaran, S.B. Kim, Uwe G. Liebert, F. Lordick, Jean-Pascal Machiels, Olivier Michielin, T.S.K. Mok, Gilberto Morgan, Radka Obermannová, K. Park, Antonio Passaro, George Pentheroudakis, Solange Peters, Martin Reck, Romane Soler, Florian Scotté, Suresh Senan, Cristiana Sessa, Elizabeth Smyth, Ross A. Soo, Jean‐Charles Soria, Jennifer O. Spicer, Florian Strasser, Josep Tabernero, Dongling Tan, Dario Trapani, Eric Van Cutsem, Henk van Halteren, Paul E. Van Schil, Giulia Veronesi, Jing Yang, Giulia Veronesi, Jing Yang - Annals of Oncology 2020 被引用: 313

  17. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sung‐Han Kim, KJ Suh, YH Park, Woong‐Yang Park, Y-L. Choi, JH Yu, Y-H Im, Ahn Js, Jy Hur, So Hyun Park, JY Kim, SJ Nam, JE Lee, SW Kim, Seung‐Koo Lee, S-A. Im, Myung‐Sun Kim, Tae‐Yop Kim, D-Y. Oh, Tae‐Yop Kim, KH Lee, DW Lee, Hyung Jun Kim, Keun‐Hwa Jung, S-B. Kim, J-H Ahn, JE Kim, JH Jung, SY Kang, MS Ahn, YW Choi, GM Kim, JH Sohn, MH Kim, SJ Koh, JK Cheon, JI Lee, ST Lim, SY Hyun, K.S. Lee, Hyung Jun Kim, M. H. Lee, JH Cho, JH Lim - The Lancet Oncology 2019 被引用: 130

  18. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nadia Harbeck - ESMO Open 2023 被引用: 52

  19. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 58

  20. A Three Dimensional DRAM (3D DRAM) Technology for the Next Decades

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S. B. Kim, K. H. Lee, S. O. Chung, S. S. Kim, I. S. Jin, B. K. Lee, C. W. Kim, Joodong Park, S. Y. Cha - IEEE Symposium on VLSI Technology and Circuits (VLSI Technology and Circuits) 2024 被引用: 42

  21. Extracting optimization and physical properties of yellowfin tuna (Thunnus albacares) skin gelatin compared to mammalian gelatins

    著者: , , - Food Hydrocolloids 2004 被引用: 283

  22. Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells.

    著者: , , , , , , , , , - 2013 被引用: 82

  23. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2024 被引用: 40

  24. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life

    著者: , , , , , , , , - ESMO Open 2022 被引用: 23